Labiotech.eu

News and Trends 20 Oct 2022

AbbVie acquires LifeArc portfolio company DJS Antibodies

AbbVie has acquired LifeArc’s portfolio company DJS Antibodies Limited, a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs). DJS’s lead program is DJS-002, a potential first-in-class lysophosphatidic acid (LPA) receptor 1 (LPAR1) antagonist antibody currently in investigational preclinical studies for the […]

October 20, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 20 Oct 2022

Partnership formed to make drug for MoCD Type A available sooner

Inceptua Early Access and Sentynl Therapeutics Inc., a U.S.-based biopharmaceutical company bringing therapies to patients living with rare diseases, have entered into a partnership. The partnership is to make Sentynl’s Nulibry available via an early access program for eligible patients with molybdenum cofactor deficiency (MoCD) Type A. MoCD Type A is a rapidly progressive autosomal […]

October 20, 2022 - 2 minutesmins - By Liza Laws

brain cancer glioblastoma divide and conquer

News and Trends 20 Oct 2022

Healthy volunteer study for tablet to treat brain cancer open for recruitment

A clinical stage drug company developing sulforaphane-based medicines for cancer treatment has started recruiting for a pharmacokinetic / pharmacodynamic trial in healthy volunteers (HV). Evgen Pharma plc also announced the start an investigator sponsored clinical study (ISS) for a glioblastoma program. The purpose of the HV study is to examine the performance of Evgen’s new […]

October 20, 2022 - 4 minutesmins - By Liza Laws

News and Trends 20 Oct 2022

Alvotech and JAMP Pharma add two biosimilar candidates for Canadian market

Alvotech and the JAMP Pharma Group have expanded their exclusive partnership to commercialize biosimilars developed and manufactured by Alvotech. The companies have added two biosimilar candidates from Alvotech’s pipeline: AVT16, a proposed biosimilar to an undisclosed immunology product and AVT33, a proposed biosimilar to an undisclosed oncology product. “We are very pleased to be expanding […]

October 20, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 20 Oct 2022

C4XD and HitGen to collaborate on inflammation hit identification project

Drug discovery company C4X Discovery Holdings plc and HitGen Inc., which develops DNA-encoded library (DEL) technology, are to collaborate on identifying novel, small molecule hits against an inflammatory target for further C4XD development. The aim of the project is to augment C4XD’s pipeline of small molecule inflammatory disease candidates for pre-clinical development and out-licensing to […]

October 20, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 20 Oct 2022

The role of long-read sequencing in validating CRISPR outcomes

Neil Ward, general manager of PacBio EMEA With applications of CRISPR across the spectrum of microbial, plant and gene therapy increasingly being realised, enthusiasm from the research community for this technology is not expected to wane. It has the potential to, among other applications, create knock-out animal models for use in research, revolutionise agriculture and […]

October 20, 2022 - 3 minutesmins - By External Contributor

News and Trends 20 Oct 2022

Enhanc3D Genomics raises £10M to advance technology platform

Enhanc3D Genomics, a functional genomics company, has raised £10 million ($11.2 million) in series A financing. The funds will be used to accelerate the development of its proprietary technology platform – GenLink3D. The financing was led by BGF and Parkwalk Advisors, with support from existing private investors and Bioqube Ventures. The funding will enable Enhanc3D […]

October 20, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 20 Oct 2022

VectorBuilder raises funds for gene delivery R&D

VectorBuilder Biotechnology (Guangzhou) Co., Ltd., a gene delivery enterprise, has completed a series C round with CNY410 million ($56.7 million). The funding was co-led by Legend Capital. The proceeds will help VectorBuilder promote the upgrading and capacity expansion of its gene delivery R&D and production technology platform, further accelerate its global business presence, and boost […]

October 20, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 20 Oct 2022

License from Helmholtz Munich will enable progression of brain cancer treatment

A treatment for one of the most aggressive and difficult to treat cancers is the focus of a licensing option that has been executed by Isotope Technologies Munich SE (ITM). The license from Helmholtz Munich was announced yesterday (October 19). The targeted radionuclide therapy with ITM-31 targets a specific protein (antigen) called CA XII, which […]

October 20, 2022 - 3 minutesmins - By Liza Laws

News and Trends 19 Oct 2022

Multi-year agreement to boost women’s reproductive health

A multi-year agreement between BioSkryb Genomics and Cooper Genomics, a reproductive health company was announced yesterday (October 18). The agreement is to license BioSkyrb’s proprietary genomic amplification technology. Cooper will utilize the Bioskryb technology to enhance their preimplantation genetic testing (PGT) capabilities. The agreement will also allow Cooper to boost BioSkyrb’s tech for the PGT […]

October 19, 2022 - 3 minutesmins - By Liza Laws

News and Trends 19 Oct 2022

Immunethep receives European Innovation Council funding for clinical trials

Immunethep, a Portuguese biotech startup, has been selected by the European Innovation Council (EIC) to receive funding from its EIC Accelerator program. Immunethep will receive initially a €2.5 million ($2.5 million) grant and is eligible for additional equity investment from the EIC Fund for a project with a total investment of €17.5 million ($17.1 million). […]

October 19, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 19 Oct 2022

CDF15 cytokine a promising therapeutic target against type 2 diabetes

CDF15 cytokine a promising therapeutic target against type 2 diabetes Researchers have conducted a review study on growth differentiation factor 15 (GDF15) — a protein expressed under physiological stress conditions — and its potential impact on the treatment for type 2 diabetes. It was led by Professor Manuel Vázquez-Carrera, from the Faculty of Pharmacy and […]

October 19, 2022 - 5 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

AbbVie acquires LifeArc portfolio company DJS Antibodies

Partnership formed to make drug for MoCD Type A available sooner

Healthy volunteer study for tablet to treat brain cancer open for recruitment

Alvotech and JAMP Pharma add two biosimilar candidates for Canadian market

C4XD and HitGen to collaborate on inflammation hit identification project

The role of long-read sequencing in validating CRISPR outcomes

Enhanc3D Genomics raises £10M to advance technology platform

VectorBuilder raises funds for gene delivery R&D

License from Helmholtz Munich will enable progression of brain cancer treatment

Multi-year agreement to boost women’s reproductive health

Immunethep receives European Innovation Council funding for clinical trials

CDF15 cytokine a promising therapeutic target against type 2 diabetes

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!